RAP-219 Hits Phase 2 Endpoints in Bipolar Mania, Clearing Path to Phase 3
RAPP sits 49% above its 52-week low of $23.75.
Summary
RAP-219 met the primary and secondary endpoints in a Phase 2 bipolar mania trial, delivering a 3.1-point placebo-adjusted improvement in YMRS at Week 3 and a 15.4-point mean reduction from baseline. Tolerability was clean, with only mild or moderate adverse events. This is the readout the company flagged as expected in its Q2 10-Q, and it validates the lead asset beyond epilepsy, where Phase 3 trials are already underway. Rapport plans to meet with the FDA in Q1 2027 on Phase 3 design, with two bipolar mania Phase 3 trials expected to start in H2 2027. The company had $436.1M in cash as of Q2, funding operations into H2 2029, so the program is financed through the next leg; the ATM programs remain available for additional capital.
At the time of this announcement, RAPP was trading at $35.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $23.75 to $52.93. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.